BioCentury | Nov 23, 2015
Strategy

More with less

...survival (PFS). In MS, Merck KGaA discontinued one program, plovamer acetate, which was acquired from Peptimmune Inc....
BioCentury | Mar 19, 2012
Strategy

Remaking Merck Serono

...stage clinical deal was for exclusive rights to the Phase I MS compound PI-2301 from Peptimmune Inc....
...Bagsvaerd, Denmark Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528), Osaka, Japan Peptimmune Inc....
...in Ph II to treat relapsing-remitting multiple sclerosis ¥1.5B ($19.5M) up front; undisclosed milestones Oct-2011 Peptimmune Inc....
BioCentury | Jan 2, 2012
Finance

Into the gap

...Development, where he started several IT companies. Bronstein was co-founder of autoimmune and inflammation company Peptimmune Inc....
BioCentury | Sep 26, 2011
Company News

Merck KGaA, Peptimmune deal

...Merck Serono S.A. division acquired exclusive, worldwide rights to multiple sclerosis (MS) candidate PI-2301 from Peptimmune...
...disclosed (see BioCentury, Jan. 19, 2009 & March 28, 2011). Merck KGaA (Xetra:MRK), Darmstadt, Germany Peptimmune Inc....
BioCentury | Mar 28, 2011
Company News

Peptimmune autoimmune, inflammation news

...acid random sequence peptide copolymer that completed Phase Ib testing to treat multiple sclerosis (MS). Peptimmune Inc....
BioCentury | Nov 22, 2010
Finance

On To The Next One

...obesity company Elixir Pharmaceuticals Inc. ; renal company Proteon Therapeutics Inc. ; and autoimmune company Peptimmune Inc....
BioCentury | Oct 11, 2010
Clinical News

Copaxone glatiramer acetate regulatory update

...In the petition, Peptimmune provided data characterizing Copaxone based on its own methods of characterization. Peptimmune...
BioCentury | Aug 31, 2009
Clinical News

PI-2301: Phase Ib data

...for Treatment and Research in Multiple Sclerosis meeting in Dusseldorf on Sept. 10. In January, Peptimmune...
...exclusive, worldwide rights to develop and commercialize PI-2301 to treat MS (see BioCentury, Jan. 19). Peptimmune Inc....
BioCentury | May 25, 2009
Finance

Ebb & Flow

...The other two were for renal company Proteon Therapeutics Inc. in March and autoimmune company Peptimmune Inc....
BioCentury | Mar 9, 2009
Finance

Ebb & Flow

...Indeed, this isn't the first introduction MPM has made. In one disclosed deal in January, Peptimmune...
Items per page:
1 - 10 of 42
BioCentury | Nov 23, 2015
Strategy

More with less

...survival (PFS). In MS, Merck KGaA discontinued one program, plovamer acetate, which was acquired from Peptimmune Inc....
BioCentury | Mar 19, 2012
Strategy

Remaking Merck Serono

...stage clinical deal was for exclusive rights to the Phase I MS compound PI-2301 from Peptimmune Inc....
...Bagsvaerd, Denmark Oncothyreon Inc. (NASDAQ:ONTY), Seattle, Wash. Ono Pharmaceutical Co. Ltd. (Tokyo:4528; Osaka:4528), Osaka, Japan Peptimmune Inc....
...in Ph II to treat relapsing-remitting multiple sclerosis ¥1.5B ($19.5M) up front; undisclosed milestones Oct-2011 Peptimmune Inc....
BioCentury | Jan 2, 2012
Finance

Into the gap

...Development, where he started several IT companies. Bronstein was co-founder of autoimmune and inflammation company Peptimmune Inc....
BioCentury | Sep 26, 2011
Company News

Merck KGaA, Peptimmune deal

...Merck Serono S.A. division acquired exclusive, worldwide rights to multiple sclerosis (MS) candidate PI-2301 from Peptimmune...
...disclosed (see BioCentury, Jan. 19, 2009 & March 28, 2011). Merck KGaA (Xetra:MRK), Darmstadt, Germany Peptimmune Inc....
BioCentury | Mar 28, 2011
Company News

Peptimmune autoimmune, inflammation news

...acid random sequence peptide copolymer that completed Phase Ib testing to treat multiple sclerosis (MS). Peptimmune Inc....
BioCentury | Nov 22, 2010
Finance

On To The Next One

...obesity company Elixir Pharmaceuticals Inc. ; renal company Proteon Therapeutics Inc. ; and autoimmune company Peptimmune Inc....
BioCentury | Oct 11, 2010
Clinical News

Copaxone glatiramer acetate regulatory update

...In the petition, Peptimmune provided data characterizing Copaxone based on its own methods of characterization. Peptimmune...
BioCentury | Aug 31, 2009
Clinical News

PI-2301: Phase Ib data

...for Treatment and Research in Multiple Sclerosis meeting in Dusseldorf on Sept. 10. In January, Peptimmune...
...exclusive, worldwide rights to develop and commercialize PI-2301 to treat MS (see BioCentury, Jan. 19). Peptimmune Inc....
BioCentury | May 25, 2009
Finance

Ebb & Flow

...The other two were for renal company Proteon Therapeutics Inc. in March and autoimmune company Peptimmune Inc....
BioCentury | Mar 9, 2009
Finance

Ebb & Flow

...Indeed, this isn't the first introduction MPM has made. In one disclosed deal in January, Peptimmune...
Items per page:
1 - 10 of 42